Below we list recent publications from the AURAH2 study:
1. The first paper published from the AURAH2 study outlines the methods that we used to set the study up in the participating clinics in London and Brighton. This paper is intended to share our experiences of setting up a multi-centre research study and provide an open account of the aims of the AURAH2 study.
2. We presented data from the AURAH2 study on PEP (post exposure prophylaxis) and PrEP (pre exposure prophylaxis) use at the European AIDS Conference in Milan in October 2017. Our data showed that the proportion of gay men aware of PEP was already high and stayed so at about 95% but the proportion who had ever taken it more than doubled from 21% to 49%. Awareness of PrEP had more than doubled, from 43% to 92%. The proportion who had actually taken it tripled, from 4% in 2013 to 11% in 2016.
3.We presented data at the 2nd European Chemsex Forum in Berlin in March 2018. Our data compared recreational drug use including poly drug use, chemsex associated drug use and individual drug use, and measures of sexual behaviour, among MSM that participated in the AURAH study (2013/2014) and the baseline questionnaire of the AURAH2 study (2015/2016). Our results showed that chemsex associated drug use had increased by almost a third between the two groups of MSM that had attended the same three clinics in London and Brighton between 2013/14 and 2015/16, and that this was mainly driven by an increase in reported use of the individual chemsex drugs. Some measures of sexual behaviour had also increased during the time between the two studies.
4. Expanding on the work that we presented at the 2nd European Chemsex Forum in March 2018, a paper was published in the BMJ Sexually Transmitted Infections journal with the full results from the comparison of recreational drug use and sexual behaviour among MSM in the AURAH and AURAH2 study. The paper can be found here and a podcast about the paper can be listened to here.
5. A paper exploring the longitudinal changes in chemsex over the AURAH2 online follow-up period was published in the International Journal of Drug Policy in 2019. The paper can be found here.